BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38685671)

  • 1. Decoding dynamic interactions between EGFR-TKD and DAC through computational and experimental approaches: A novel breakthrough in lung melanoma treatment.
    Meher RK; Mir SA; Singh K; Mukerjee N; Nayak B; Kumer A; Zughaibi TA; Khan MS; Tabrez S
    J Cell Mol Med; 2024 May; 28(9):e18263. PubMed ID: 38685671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potent EGFR-TKD inhibitors from NPACT database through combined computational approaches.
    Mir SA; Muhammad A; Padhiary A; Ekka NJ; Baitharu I; Naik PK; Nayak B
    J Biomol Struct Dyn; 2023; 41(21):12063-12076. PubMed ID: 36695102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In Silico and In Vitro Evaluations of Fluorophoric Thiazolo-[2,3-b]quinazolinones as Anti-cancer Agents Targeting EGFR-TKD.
    Mir SA; Dash GC; Meher RK; Mohanta PP; Chopdar KS; Mohapatra PK; Baitharu I; Behera AK; Raval MK; Nayak B
    Appl Biochem Biotechnol; 2022 Oct; 194(10):4292-4318. PubMed ID: 35366187
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Meher RK; Mir SA; Anisetti SS
    J Biomol Struct Dyn; 2024 May; 42(8):4169-4184. PubMed ID: 37272907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of tripeptides against tyrosine kinase domain of EGFR for lung cancer cell inhibition by in silico and in vitro studies.
    Kiriwan D; Seetaha S; Jiwacharoenchai N; Tabtimmai L; Sousa SF; Songtawee N; Choowongkomon K
    Chem Biol Drug Des; 2022 Mar; 99(3):456-469. PubMed ID: 34923743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro.
    Biegański P; Godel M; Riganti C; Kawano DF; Kopecka J; Kowalski K
    Bioorg Chem; 2022 Feb; 119():105514. PubMed ID: 34864281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions.
    Saini N; Grewal AS; Lather V; Gahlawat SK
    Chem Biol Interact; 2022 May; 358():109901. PubMed ID: 35341731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel heptamethine cyanine dye-erlotinib conjugates as antitumor agents.
    Yang X; Hou Z; Wang D; Mou Y; Guo C
    Bioorg Med Chem Lett; 2020 Dec; 30(23):127557. PubMed ID: 32949719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways.
    Shan F; Shao Z; Jiang S; Cheng Z
    Cancer Med; 2016 Nov; 5(11):3166-3175. PubMed ID: 27726288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic and thermodynamic insights into interaction of erlotinib with epidermal growth factor receptor: Surface plasmon resonance and molecular docking approaches.
    Mohammadzadeh-Asl S; Aghanejad A; Yekta R; de la Guardia M; Ezzati Nazhad Dolatabadi J; Keshtkar A
    Int J Biol Macromol; 2020 Nov; 163():954-958. PubMed ID: 32653374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
    Dai CH; Shu Y; Chen P; Wu JN; Zhu LH; Yuan RX; Long WG; Zhu YM; Li J
    Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3786-3798. PubMed ID: 30315932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
    Li YL; Hu X; Li QY; Wang F; Zhang B; Ding K; Tan BQ; Lin NM; Zhang C
    Mol Med Rep; 2018 Oct; 18(4):3882-3890. PubMed ID: 30106133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib.
    Amri J; Molaee N; Baazm M; Karami H
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2781-2787. PubMed ID: 31554377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR
    Abo Al-Hamd MG; Tawfik HO; Abdullah O; Yamaguchi K; Sugiura M; Mehany ABM; El-Hamamsy MH; El-Moselhy TF
    J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2241674. PubMed ID: 37548154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-Regulation of MiRNA-125a-5p Inhibits Cell Proliferation and Increases EGFR-TKI Induced Apoptosis in Lung Cancer Cells.
    Amri J; Molaee N; Karami H
    Asian Pac J Cancer Prev; 2019 Nov; 20(11):3361-3367. PubMed ID: 31759360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and Synthesis of Non-Covalent Imidazo[1,2-
    Kumar M; Joshi G; Arora S; Singh T; Biswas S; Sharma N; Bhat ZR; Tikoo K; Singh S; Kumar R
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33803355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
    Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
    Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment.
    Shi P; Oh YT; Zhang G; Yao W; Yue P; Li Y; Kanteti R; Riehm J; Salgia R; Owonikoko TK; Ramalingam SS; Chen M; Sun SY
    Cancer Lett; 2016 Oct; 380(2):494-504. PubMed ID: 27450722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of JAK1/2 can overcome EGFR-TKI resistance in human NSCLC.
    Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
    Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel 2-(5-Aryl-4,5-Dihydropyrazol-1-yl)thiazol-4-One as EGFR Inhibitors: Synthesis, Biological Assessment and Molecular Docking Insights.
    Al-Warhi T; El Kerdawy AM; Said MA; Albohy A; Elsayed ZM; Aljaeed N; Elkaeed EB; Eldehna WM; Abdel-Aziz HA; Abdelmoaz MA
    Drug Des Devel Ther; 2022; 16():1457-1471. PubMed ID: 35607598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.